World leader in vector vaccine technology for poultry, the CEVA Santé Animale group in Libourne has announced a 50-million euro investment to bolster its biology production capacities abroad at its campuses in Hungary and the United States.
These new facilities should allow the group to double the volume of vaccine products destined for poultry. It will also help launch new products.
CEVA will invest 50 million euros in Budapest (370 people) for the creation of 3,700 m² of cleanrooms and in Lexana (200 people) to construct 3,100 m² of cleanrooms.
Already present in 110 countries across the world (3,750 employees worldwide – 766 million euros turnover in 2014), the Gironde animal health group, ranked in the top 10 animal health groups in the world, invests 10% of its revenue in research.
Each year, one broiler chicken out of four in the world is vaccinated with the Gironde group’s products.
(Source: Objectif Aquitaine, La Tribune 06/07/2015)